You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 20, November 26, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Viral Infections
 •Pulmonary Diseases, Other
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic

Inhibition of SARS-Associated Coronavirus Infection and Replication by RNA Interference

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: A novel coronavirus has been identified as the etiologic agent of severe acute respiratory syndrome (SARS),1-3 for which there is no specific treatment. Small interfering RNAs (siRNAs) are double-stranded RNAs that direct sequence-specific degradation of messenger RNA in mammalian cells.4 It is also possible, however, that siRNAs could specifically interfere with viral RNA.

Methods

We designed six 21-mer SARSis (siRNAs [GENSET SA Ltd, Paris, France] targeting different sites of the replicase 1A region of the SARS coronavirus [SARS-CoV] genome; siRNA sequences in the senses strands: GUGAACUCACUCGUGAGCUCdTdT [SARSi-1]; GUACCCUCUUGAUUGCAUCdTdT [SARSi-2]; GAGUCGAAGAGAGGUGUCUdTdT [SARSi-3]; GCACUUGUCUACCUUGAUGdTdT [SARSi-4]; CCUCCAGAUGAGGAAGAAGdTdT [SARSi-5]; and GGUGUUUCCAUUCCAUGUGdTdT [SARSi-6]). We then performed 3 in vitro experiments to test their antiviral effects. In the first, we transfected monkey kidney cells (FRhk-4) with 1 of the 6 siRNAs. In addition to these 6 groups of cells, we also created 2 groups of control cells—1 transfected with an unrelated siRNA targeting luciferase . . . [Full Text of this Article]

Ming-Liang He, PhD; Bojian Zheng, MD, PhD; Ying Peng, MD, PhD; Joseph S. M. Peiris, PhD; Leo L. M. Poon, PhD; Kwok Y. Yuen, MD, PhD; Marie C. M. Lin, PhD; Hsiang-fu Kung, PhD; Yi Guan, PhD
University of Hong Kong
Hong Kong, China



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection
Cheng et al.
Clin. Microbiol. Rev. 2007;20:660-694.
ABSTRACT | FULL TEXT  

Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release
Lu et al.
Proc. Natl. Acad. Sci. USA 2006;103:12540-12545.
ABSTRACT | FULL TEXT  

The Prospect of Silencing Disease Using RNA Interference
Shankar et al.
JAMA 2005;293:1367-1373.
ABSTRACT | FULL TEXT  

Clinical Issues and Research in Respiratory Failure from Severe Acute Respiratory Syndrome
Levy et al.
Am. J. Respir. Crit. Care Med. 2005;171:518-526.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.